Obstetrics & Gynaecology Search
Obstetrics & Gynaecology Obstetrics & Gynaecology
Most Read Articles
Olaparib-bevacizumab PFS benefit in ovarian cancer greatest following upfront surgery
Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.

Early protection against rotavirus infections

12 Dec 2019
Rotavirus (RV) is highly contagious. Globally, 2 million children are hospitalized and more than 500,000 die annually from RV associated gastroenteritis. Therefore, vaccination is imperative for the prevention of RV infections.

Related MIMS Drugs

ROTARIX
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Olaparib-bevacizumab PFS benefit in ovarian cancer greatest following upfront surgery
Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.